Biogen last week suffered...

...a blow in federal court, when a judge ruled one if its remaining patents for Tecfidera, a multiple sclerosis drug, invalid. This paves the way for Mylan's generic Tecfidera, which still must earn FDA approval. For the treatment of multiple sclerosis under the pharmacy benefit, Tecfidera currently holds preferred status for 12% of all covered lives, growing to 53% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 6/24/20